The hematopoietic growth factors, granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colonystimulating factor (G-CSF), enhance the effector functions of mature myeloid cells, including the interaction with vascular endothelium. We examined the direct effect of recombinant human GM-CSF (rhGM-CSF) and recombinant human G-CSF (rhG-CSF) on the growth and function of cultured human umbilical vein endothelial cells (HUVEC). Endothelial cell growth supplement (ECGS) increased the proliferation of passaged and primary cells by 305% f 45% (mean k SEM, n = 5, P < .01) over control cells at 4 days; GM-CSF and G-CSF had no effect. Endothelial cell procoagulant activity was increased after 4-hour incubation with recombinant interleukin-1 p (IL-1p) 10 U/mL and recombinant tumor necrosis factor (TNF) 10 U/mL t o 1.721% -f: 376% (n = 7, P < .005) and 247% -f: 71% (n = 4) of control levels, respectively. ylnterferon (7-IFN) 50 U/mL had no direct effect of its own but was able t o prime the response t o IL-1p. There was no direct or priming effect of GM-CSF (1 ng t o 1 pg/mL) on the expression of procoagulant activity in endothelial cells.
Lack of Effect of Granulocyte-Macrophage and Granulocyte Colony-Stimulating Factors on Cultured Human Endothelial Cells
The hematopoietic growth factors, granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colonystimulating factor (G-CSF), enhance the effector functions of mature myeloid cells, including the interaction with vascular endothelium. We examined the direct effect of recombinant human GM-CSF (rhGM-CSF) and recombinant human G-CSF (rhG-CSF) on the growth and function of cultured human umbilical vein endothelial cells (HUVEC). Endothelial cell growth supplement (ECGS) increased the proliferation of passaged and primary cells by 305% f 45% (mean k SEM, n = 5, P < .01) over control cells at 4 days; GM-CSF and G-CSF had no effect. Endothelial cell procoagulant activity was increased after 4-hour incubation with recombinant interleukin-1 p (IL-1p) 10 U/mL and recombinant tumor necrosis factor (TNF) 10 U/mL t o 1.721% -f: 376% (n = 7, P < .005) and 247% -f: 71% (n = 4) of control levels, respectively. ylnterferon (7-IFN) 50 U/mL had no direct effect of its own but was able t o prime the response t o IL-1p. There was no direct or priming effect of GM-CSF (1 ng t o 1 pg/mL) on the expression of procoagulant activity in endothelial cells.
ASCULAR ENDOTHELIUM is a dynamic interface
V between circulating blood components and extravascular tissues. It is a multifunctional organ that can respond to a wide variety of stimuli to participate actively in maintenance of hemostatic balance, regulation of hematopoiesis, and control of immune and inflammatory phenomena. Endothelial cells engage in reciprocal interactions with other cells, mediated by cytokines and other humoral mediators, as well as by cell-cell adhesion pathways. Stimulated endothelial cells produce cytokines such as interleukin-1 (IL-1) and IL-6,'" platelet-activating factor (PAF),4 platelet-derived growth factor (PDGF): and the hematopoietic growth factors, granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), and macrophage colony-stimulating factor
In addition, the growth and function of cultured endothelial cells can be modulated by cytokines. ?-Interferon (y-IFN) augments endothelial cell growth, whereas IL-1 and tumor necrosis factor (TNF) are inhibitory.' These cytokines increase the surface expression of adhesion receptors and class I and I1 HLA molecules and enhance the adhesiveness of endothelium for leucocytes.*,' They also influence the hemostatic and fibrinoIytic activities of endothelial cells. IL-1, TNF, and y-IFN have been reported to increase tissue factor
In response to IL-1 and TNF, tissue plasminogen activator (tPA) synthesis is either unchanged or decreased, while plasminogen activator inhibitor-1 (PAI-1) synthesis is increased.'"'' Furthermore, IL-1 and TNF can also stimulate endothelial cells to produce GM-CSF, G-CSF, and M-CSF~S'~,'~ cytokines that enhance the function of mature phagocyte^.'^,'^ Endothelial cells also produce these factors when exposed to modified lowdensity lipoproteins,20which may play a role in the pathogenesis of atheromatous plaques.
Recently, human endothelial cells themselves have been reported to express receptors for GM-CSF and to prolifer-(M-CSF).~ GM-CSF and G-CSF (1 ng/mL t o 1 wg/mL) had no effect on the expression of either tissue plasminogen activator (tPA) or plasminogen activator inhibitor-1 (PAI-1) by endothelial cells. The secretion of tPA by endothelial cells was increased, however, after 24-hour incubation with thrombin 4 U/mL (314% f 72% of control levels, n = 5, P < .025). The production of PAL1 was increased by TNF 200 U/mL (241% 2 44% of control, n = 3, P < .005), thrombin 4 U/mL (180% f 12% of control, n = 5, P < ,0005) and IL-1 p 10 U/mL (275% f 44% of controls, n = 5, P < .0005). In four experiments, endothelial cells showed no specific binding of '%GM-CSF, whereas peripheral blood (PB) neutrophils demonstrated the presence of 802 +. 78 high-affinity receptors for GM-CSF. Thus, we found no effect of rhGM-CSF or rhG-CSF on the proliferation of HUVEC or the expression of procoagulant and fibrinolytic activities by these cells. These findings are in accordance with the lack of demonstrable receptors for GM-CSF on cultured HUVEC. ate and migrate in response to GM-CSF and G-CSF." Production of these cytokines by the activated endothelial cell could thus create an autocrine positive feedback loop.
Early clinical trials have established the role of GM-CSF and G-CSF in management of bone marrow (BM) hypoplastic states, particularly after myelosuppressive chemotheraPY.1q,u,23 The direct effect of these cytokines on vascular endothelium is of particular clinical relevance, especially as central venous thrombose^^.^^ and the endothelial leak syndromez6 have been reported at high doses of GM-CSF. We therefore wished to study the effects of recombinant human GM-CSF (rhGM-CSF) and recombinant human G-CSF (rhG-CSF) on proliferation of cultured human umbilical vein endothelial cells (HUVEC) and on expression of procoagulant activity, tPA, and PAI-1 by these cells. Chugai, Japan, endothelial cell growth supplement (ECGS) from Sigma, and "'I-GM-CSF from Amersham, UK.
MATERIALS AND METHODS

Cytokines
The biologic activity of both unlabeled and iodinated GM-CSF was determined by proliferation assays using a GM-CSFdependent cell line and by flow cytometric priming assay of the neutrophil respiratory burst?' I2'I-GM-CSF specific activity was determined by a combination of enzyme-linked immunosorbent assay (ELISA) (Medgenix Diagnostics, Bucks, England) and biologic assays (described above), which gave comparable results and determination of maximum binding capacity and self-displacement activity as described pre~iously.*~~*~ RPMI 1640, Iscove's modified Dulbecco's medium (IMDM), M-199, fetal calf serum (FCS), penicillinistreptomycin, and phosphate-buffered saline (PBS) were obtained from GIBCO Laboratories, Uxbridge, UK. TrypsinEDTA, fibronectin, and collagenase were obtained from Boehringer Mannheim. 3,(4,5-Dimethylthiazol-2-yl)2,5-diphenyltetrazolium bromide (MTT) and EGTA were obtained from Sigma. The chromogenic substrate S2222 was obtained from Kabi (Stockholm, Sweden). Factor VII, 11, IX, and X concentrates were supplied by Blood Products Laboratory, Elstree, England. Rabbit thromboplastin was obtained from Diagen, UK. Anti-von Willebrand factor monoclonal antibody (vWF MoAb) was obtained from Dako, UK.
Cell cultures. HUVEC were harvested from umbilical cords within 6 hours of delivery by collagenase treatment (0.1%)30 and grown to confluence on fibronectin-coated (2 pg/cm*) plastic in IMDM or RPMI 1640 with 20% FCS, penicillinistreptomycin (100 UimLilOO pg/mL), ECGS (25 pg/mL), and heparin (50 UimL). Cells were identified by typical cobblestone morphology and granular staining pattern with vWF MoAb. Cultures were passaged with trypsinEDTA (0.05%/.02% in PBS). The mycoplasma-free endothelial cell line EAhy926" was a gift from Dr C. J. Edgell, University of North Carolina, Chapel Hill.
Passaged (1 through 7) HUVEC and primary cultures were seeded (2 x lo3 cells per well) in 96-well fibronectin-coated microtiter plates. Cytokines were either added at the time of seeding or added to cultures at 50% confluence after 48-hour serum starvation. A standard MTT assa?
was used to quantitate cell numbers. Cells were rinsed twice with medium s before being incubated with MTT, 1 mg/mL in medium, 100 pL/well, for 2 hours at 37°C. The incubation solution was aspirated, and 100 pL dimethyl sulfoxide (DMSO) was added to each well to solubilize the formazan crystals. The change in absorbance was read at 570 nm on an MR 700 Microplate Reader (Dynatech Laboratories).
The validity of this assay as a measure of cell proliferation was tested in two ways. First, the assay was calibrated by seeding known numbers of cells in 96-well tissue culture plates. Eight wells were used for each data point. After a 2-hour incubation to allow the cells to adhere, the wells were rinsed twice with medium and an MTT assay was performed on half the wells. On the other four wells of each data point, cells were removed by trypsin/EDTA treatment and counted on a Neiubauer counting chamber. The number of cells removed from each well was within 5% to 10% of the number seeded. Figure 1 (inset) shows a calibration curve of absorbance units against cell numbers derived from three separate experiments. Second, in two parallel experiments, the results of 'H-thymidine incorporation were compared with those from the M7T assay. Microtiter plates were set up for proliferation assays as described in the Materials and Methods section. Half the wells were pulsed with 'H-thymidine (1 KCi per well) from 7 to 24 hours after cytokines were added. The cells in the other half of the plate were allowed to grow for 48 hours before the MTT assay was performed. The results of 3H-thymidine uptake were comparable to the cell numbers obtained from the MTT assay using the calibration curve (data not shown).
Subconfluent HUVEC (passages 1 and 2) in 96-well microtiter plates were washed twice with medium and then stimulated with cytokines in medium with 10% FCS. The surface expression of procoagulant activity (PCA) was measured by a two-stage amidolytic assay using the chromogenic substrate S222234,35 which measures the conversion of factor X to its activated form. Plates were washed three times with medium and then incubated for 3 minutes at 37°C with 100 pL per well of M199 without phenol red containing factor VI1 1 UimL and factor X 1 UimL. S2222 1 mmol/L was added (50 pL per well), and incubation was continued until optimum color developed (10 to 20 minutes). The change in optical density at 410 nm was quantified using an Procoagulant assays.
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MR 700 microplate reader (Dynatech Laboratories). The concentration of procoagulant activity was calculated from a standard curve obtained using rabbit thromboplastjn (1/100,000 dilution rabbit thromboplastin = 1 U PCA).
Confluent HUVEC (first and second passage) in =-well plates (Costar, Cramlington, Northumbria, UK) were washed and stimulated in triplicate wells with cytokines in 1% FCS. After 24 hours, culture medium was removed and centrifuged for 3 minutes at 15,000 6 to remove cell debris, and aliquots were frozen at -70°C after addition of 0.01% Tween 80. Monolayers were then washed once and treated with 0.5% Triton X, and cellular extracts were frozen at -70°C.
Total human tPA (uncomplexed and inhibitor-bound) was determined using enzyme immunoassay (Biopool, Umea, Sweden). Background binding was eliminated by use of quenching antibodies. Each test sample was incubated in paired adjacent wells. To one well an excess of the coating antibody in solution was added to block binding of tPA antigen. The other well contained an irrelevant isotype-matched antibody. Hence, the difference in assay response between the two wells would be highly specific for tPA antigen. The concentration of tPA antigen in each sample was extrapolated from a standard curve obtained using single-chain recombinant human tPA (rhtPA). The interassay variability ,was less than 10%. PAI-1 antigen (both active and "latent" forms) was assayed by enzyme immunoassay, using a similar double-antibody principle to control for immunologic specificity @iopool). The concentration of PAI-1 in each sample was ,calculated from a standard curve obtained using PAI-1 standard plasma supplied by Biopool. The interassay variability was 10%.
HUVEC (third through fourth passage) were grown to confluence as described and detached using trypsinEDTA or E G T e alone. After two washes with RPMI 1640120% FCS, cells were resuspended in RPMI 1640/2% FCS at 4 x 10' cellsiml; IO' cells were incubated with varying concentrations of '=I-GM-CSF (Specific activity 4.2 to 6.8 x 105 cpdng) for 4 hours at 23°C. Each sample was incubated with or without a 50-fold excess of unlabeled GM-CSF to control for nonspecific binding. Triplicate samples were layered onto chilled 20% glycerol in RPMI 1640, centrifuged at 7,00(% for 60 seconds, and snap-frozen in liquid nitrogen. The associated radioactivity of the cell pellet was measured in an automated y-counter (LKB, Milton Keynes, UK). An identical protocol used human peripheral neutrophils purified by dextran sedimentation of whole blood, followed by centrifugation over Lymphoprep 1077 (Nycomed, Oslo, Norway).
tPA and PAI-I assays.
GM-CSF receptor assays.
RESULTS
The effect of cytokines on endothelial cell proliferation was studied by culturing cells in the continuous presence of ECGS 50 hg/mI,, IL-lP 5 U/mL, GM-CSF 1 ng/mL to 1 kg/mL, G-CSF 1 ng/mL to 100 ng/mL, or diluent as control in medium with 20% FCS. Cell proliferation at various time points was quantitated using an MTT assay and converting the absorbance values into actual cell numbers using the calibration curve (Fig 1,  inset) . The data for passaged and primary cells was combined because there was no difference between the two. Figure 1 shows that when present continuously, ECGS 50 pg/mL increased endothelial cell prqliferation by 305% +-45% (n = 5, P < .01) as compared with controls at 4 days; this enhancement increased to 596% +-137% (n = 5, P < .01) after 7 days in culture. Neither GM-CSF nor G-CSF had any effect on cell growth at concentrations ranging from 1 ng/ml to 1 &mL. ILlP 5 .U/mL produced a
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small decrease in growth at 4 days to 85% +-11% (n = 5 , not significant by paired t-test). In an attempt to maximize any response to added cytokines, in a second series of experiments, cultures were grown to s 50% confluence in full culture medium and then "starved" for 48 hours in 1% FCS with 0.5% bovine serum albumin (BSA, fraction V, Sigma). Cells were then treated with cytokines in the presence of 2% FCS, and cell proliferation was assessed at various times by MTT assay. Data from primary and passaged cells were pooled. Again, ECGS enhanced proliferation of HUVEC by 342% 2 63.2% (n = 10, P < .01) over control cells at 4 days (Fig 2) . There was no effect of GM-CSF (1 to 100 ng/mL), G-CSF (1 to 100 ng/mL) or IL-1P (1 to 10 U/mL) in this assay system.
The effect of cytokines on expression of procoagulant activity (PCA) by HUVEC was studied by incubating confluent cultures with cytokines in medium with 10% FCS for varying times. Unstimulated HUVEC contained low levels of PCA (3.22 +-0.44 PCA U per well, mean +-SD, n = 10). After 4-hour incubation with IL-lp, 10 U/mL, PCA increased to 1,721% 2 376% of control levels (n = 7, P < .005), whereas TNF 10 U/mL produced a more modest increase of 247% 5 71% of control levels (n = 4) (Fig 3) . y I F N (50 U/mL) and GM-CSF (1 to 100 ng/mL) had DO direct effect on PCA. y-IFN, however, was able to augment the PCA production by endothelial cells in response to IL-1P. Figure 4 , representative of two experiments, shows the effect of a 16-hour preincubation with 7-IFN (50 U/mL) before addition of IL-1 (1 to 10 U/mL) for 4 more hours. GM-CSF (1 to 100 ng/mL) had no effect in three experiments. In two other experiments, GM-CSF was added simultaneously with IL-lp, and incubation pro- chosen because it has been reported to result in near optimum tPA expression by primary cultured endothelial cells. 36 The unstimulated level of tPA antigen secreted by HUVEC is low (2.4 2 0.2 ng/l@ cells, n = 5 ) and increases to 314% f 72% of control levels (n = 5, P < .025) after 24-hour incubation with thrombin 4 U/mL (Fig 5) . IL-lP (10 U/mL) produced a small but insignificant decrease to 85% -C 9% of control levels (n = 3), whereas GM-CSF (1 to 100 ngimL) and G-CSF (1 to 100 ng/mL) had no effect on tPA expression. Cell-associated tPA antigen levels were below the level of detection of the assay.
Secreted PAI-1 antigen expression by HUVEC was increased to 275% 2 44% and 180% r 12% of controls (n = 5, P < .0005 for both) after 24-h incubation with IL-lP 10 U/mL and thrombin 4 U/mL, respectively (Fig 6) . TNF (200 U/mL), in the same time period, produced an increase to 241% 5 44% of control levels (n = 3, P < .005).
Similarly, cell-associated PAI-1 antigen was increased to 266% 2 108% (n = 3, NS by Student's t test) and 195% ? 54% (n = 3, NS) of control levels after 24-hour incubation with 1L-1 and thrombin, respectively. GM-CSF and G-CSF had no effect on secreted or cellular PAI-1. 
GM-CSF receptor assay.
In view of the lack of effect of GM-CSF on HUVEC in our system, we wished to determine the number of GM-CSF receptors present on these cells. HUVEC at third and fourth passage, pooled from at least three umbilical cords, were detached by treatment with trypsinEDTA and used in a binding assay with "'1-GM-CSF as detailed in the Materials and Methods section. In two experiments, no specific binding of IsI-GM-CSF was noted (data not shown). In case trypsin treatment might have cleaved off any GM-CSF receptors on the cells, two other experiments were performed using HUVEC grown on gelatin (0.05%)-coated flasks, and removed by treatment with 1 mmol/L EGTA (10 minutes at 37°C). Again, no specific binding of '"1-GM-CSF to endothelial cells was observed (Fig 7A) , whereas peripheral blood (PB) neutrophils exhibited significant specific binding. specific binding of '"1-GM-CSF than neutrophils, but 25 receptors per endothelial cell should give binding values 50% above background. The endothelial line EAh~926'~ has also been reported to express GM-CSF receptors and to respond to this cytokine." We therefore repeated our assay on cells of this line, detached from plastic tissue culture flasks by EGTA treatment. These cells did not demonstrate any specific binding of "'1-GM-CSF in two experiments (data not shown).
DISCUSSION
The HUVEC used in these studies display a range of responses to cytokines. Proliferation is enhanced in response to ECGS, but not to IL-1p. IL-1p and TNF directly enhance cell-associated PCA whereas y-IFN, although not having any direct effect on its own, primes the IL-1p response. This confirms previous reports.'"~" Secretion of tPA by HUVECs is enhanced by thrombin, but not by IL-1p and TNF. All three agonists, however, increase both secreted and cellular PAI-1 antigen. These observations are in keeping with those of other inve~tigators.'~''~ In these responses, the HUVEC in our culture system behave in a manner similar to that reported for other cultured human endothelial cells.
We have observed a lack of response to GM-CSF and G-CSF, however, in all the parameters described above. The failure of cultured HUVEC to proliferate in response to GM-CSF and G-CSF in our studies contrasts with the reports by Bussolino et a12' 337 on multiply passaged endothelial cells. In addition, culturing cells up to the eighth passage in the continuous presence of GM-CSF (10 to 100 ng/mL) did not induce any responsiveness to the growth factor (data not shown). The lack of effect of GM-CSF on HUVEC cell-associated PCA has been noted by other investigators."
rhG-CSF has been reported to increase plasminogen activator activity in bovine aortic endothelial cells. 38 We noted no effect on TPA or PAI-1 antigen levels in primary human endothelial cells at similar doses of the same recombinant product. The functional assays for plasminogen activator activity used by Kojima et aI3' do not distinguish between urokinase-type plasminogen activators and tPA, however, whereas our assays are specific for tPA. Furthermore, the type of plasminogen activator produced can vary with the origin of the endothelial cells as well as the conditions of ~t i m u l a t i o n .~~,~~.~ Finally, in keeping with the lack of response to GM-CSF, we failed to demonstrate any GM-CSF receptors on either primary human endothelial cells or the endothelial cell line EAhy 926, although in the same experiments, neutrophils expressed 802 f 78 high-affinity receptors. This again contrasts with reports by Bussolino et al, who observed 423 5 187 high-affinity receptors on human endothelial cells." The reason for this discrepancy is not clear, but it suggests that expression of GM-CSF receptors by cultured endothelial cells and the ability of these cells to respond to these growth factors are critically dependent on culture conditions. One should not assume that GM-CSF influences endothelial cell function in vivo.
